Markets:

Overview

News

Currencies

International

Treasuries

Arcellx, Inc. - Common Stock (NQ:ACLX)

114.39 +0.10 (+0.09%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Arcellx, Inc. - Common Stock

< Previous 1 2 Next >

Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

March 13, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

Halper Sadeh LLC is Investigating Whether BCO, THR, ACLX are Obtaining Fair Deals for their Shareholders

March 05, 2026

From Halper Sadeh LLC

Via GlobeNewswire

Halper Sadeh LLC is Investigating Whether ACLX, VRE, EHAB are Obtaining Fair Deals for their Shareholders

March 04, 2026

From Halper Sadeh LLC

Via GlobeNewswire

Halper Sadeh LLC is Investigating Whether ACLX, EHAB, VRE are Obtaining Fair Deals for their Shareholders

February 24, 2026

From Halper Sadeh LLC

Via GlobeNewswire

Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

February 23, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

ACLX Stock Alert: Halper Sadeh LLC is Investigating Whether Arcellx, Inc. is Obtaining a Fair Price for its Shareholders

February 23, 2026

From Halper Sadeh LLC

Via Business Wire

Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel

February 23, 2026

From Arcellx, Inc.

Via Business Wire

Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel’s D-Domain Binder

February 04, 2026

From Arcellx, Inc.

Via Business Wire

Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings

January 21, 2026

From Arcellx, Inc.

Via Business Wire

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

December 06, 2025

From Arcellx, Inc.

Via Business Wire

Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition

November 18, 2025

From Arcellx, Inc.

Via Business Wire

Arcellx Provides Third Quarter 2025 Financial Results

November 05, 2025

From Arcellx, Inc.

Via Business Wire

Arcellx to Present New Data for Its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and Exposition

November 03, 2025

From Arcellx, Inc.

Via Business Wire

Arcellx to Participate at the 2025 Morgan Stanley Global Healthcare Conference

September 03, 2025

From Arcellx, Inc.

Via Business Wire

Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights

August 07, 2025

From Arcellx, Inc.

Via Business Wire

Arcellx Announces Its Participation at TD Cowen’s 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025

May 21, 2025

From Arcellx, Inc.

Via Business Wire

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

May 14, 2025

From Arcellx, Inc.

Via Business Wire

Arcellx Provides First Quarter 2025 Financial Results and Business Highlights

May 08, 2025

From Arcellx, Inc.

Via Business Wire

Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

March 20, 2025

From Arcellx, Inc.

Via Business Wire

Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights

February 27, 2025

From Arcellx, Inc.

Via Business Wire

Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference

February 26, 2025

From Arcellx, Inc.

Via Business Wire

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition

December 08, 2024

From Arcellx, Inc.

Via Business Wire

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights

November 07, 2024

From Arcellx, Inc.

Via Business Wire

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study

November 05, 2024

From Arcellx, Inc.

Via Business Wire

Arcellx Provides Second Quarter 2024 Financial Results and Business Updates

August 08, 2024

From Arcellx, Inc.

Via Business Wire

Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

May 09, 2024

From Arcellx, Inc.

Via Business Wire

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

May 09, 2024

From Gilead Sciences, Inc.

Via Business Wire

Arcellx Provides First Quarter 2024 Financial Results

May 09, 2024

From Arcellx, Inc.

Via Business Wire

Arcellx to Participate in Two Upcoming Investor Conferences

May 07, 2024

From Arcellx, Inc.

Via Business Wire

Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference

April 04, 2024

From Arcellx, Inc.

Via Business Wire

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.